His biological study deals with issues like Animal science, which deal with fields such as Hay and Herd. His research brings together the fields of Animal science and Herd. His study looks at the intersection of Pipeline transport and topics like Mechanical engineering with Pipeline (software). Complete remission and CHOP are the two main areas of interest in his Chemotherapy studies. Richard A. Larson connects CHOP with Chemotherapy in his study. He links relevant research areas such as Pipeline (software) and Transient (computer programming) in the realm of Operating system. Transient (computer programming) is closely attributed to Operating system in his study. Richard A. Larson integrates Genetics and Computational biology in his studies. In his works, he performs multidisciplinary study on Computational biology and Gene.
His Internal medicine study frequently draws parallels with other fields, such as Myeloid leukemia. His study ties his expertise on Chemotherapy together with the subject of Genetics. His Chemotherapy study frequently draws connections between adjacent fields such as Genetics. His study deals with a combination of Gene and Biochemistry. He connects Biochemistry with Gene in his research. Leukemia is closely attributed to Immunology in his work. His study ties his expertise on Leukemia together with the subject of Immunology. In his works, Richard A. Larson undertakes multidisciplinary study on Oncology and Cancer research. He performs multidisciplinary studies into Cancer research and Oncology in his work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner.
Journal of Clinical Oncology (2003)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum.
The antioxidants of higher plants
Richard A. Larson.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll.
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
Lewis R. Silverman;Erin P. Demakos;Bercedis L. Peterson;Alice B. Kornblith.
Journal of Clinical Oncology (2002)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio;Dong-Wook Kim;Surapol Issaragrisil;Gabriel Etienne.
The New England Journal of Medicine (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: